<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822975</url>
  </required_header>
  <id_info>
    <org_study_id>2018-031</org_study_id>
    <nct_id>NCT03822975</nct_id>
  </id_info>
  <brief_title>Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI</brief_title>
  <acronym>BRIGHT-4</acronym>
  <official_title>Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During: a Multicenter, Randomized, Open-label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to investigate if the bivaliruding with prolonged full dose infusion
      after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for
      patients with STEMI treated with emergency PCI. A total of 6000 STEMI patients will be
      enrolled and randomly assigned to receive bivalirudin or heparin during emergency PCI in a
      1:1 ratio. This study will provide key evidence for peri-operative anticoagulant therapy
      decisions in STEMI patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause death or BARC type 3~5 bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>BARC=Bleeding academic research consortium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC type 3-5 bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>BARC=Bleeding academic research consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebral events (MACE)</measure>
    <time_frame>30 days</time_frame>
    <description>MACE is defined as a composite of all cause death, recurrent myocardial infarction, stroke or ischemic driven target vessel revascuarlization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net adverse clinical events (NACE)</measure>
    <time_frame>30 days</time_frame>
    <description>NACE is defined as a composite of MACE or BARC type 3-5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause death or BARC type 2-5 bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>BARC=Bleeding academic research consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARC type 2-5 bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>BARC=Bleeding academic research consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>30 days</time_frame>
    <description>Definite or probable stent thrombosis according to Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>30 days</time_frame>
    <description>defined as platelet counts less than 150*10^9/L after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin with prolonged full dose infusion during primary PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin alone during primary PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is &lt;225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is &gt;225 seconds.</description>
    <arm_group_label>Bivalirudin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>unfractionated Heparin</intervention_name>
    <description>Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT &lt;225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is &gt;225 seconds.</description>
    <arm_group_label>Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any age;

          -  STEMI patients undergoing primary PCI with ST elevation≥1mm in≥2 contiguous leads or
             new LBBB with symptom onset 48h;

          -  Patients requiring staged revascularization of non-culprit vessels within 30 days may
             be enrolled. In such cases the same antithrombotic agents and PCI procedures must be
             used in the staged procedure consistent with the index procedure PCI, in particular
             the assigned antithrombin agent heparin vs. bivalirudin);

          -  Dual antiplatelet drugs must be administrated according to guidelines before PCI
             (loading doses and maintenance doses of aspirin and clopidogrel or ticagrelor);

          -  The subject or legal representative has been informed of the nature of the study,
             understood the provisions of the protocol, was able to ensure adherence, and signed
             informed consent.

        Exclusion Criteria:

          -  Not suitable for emergency primary PCI;

          -  STEMI treated by thrombolysis;

          -  Patients received heparin, LMWH, fondaparinux, bivalirudin, or GPI within 48 hours
             before the index PCI;

          -  Mechanical complications (such as ventricular septal rupture, papillary muscle rupture
             with acute mitral regurgitation, etc.);

          -  Known allergy or contraindications to heparin, bivalirudin, aspirin, or both
             clopidogrel and ticagrelor

          -  Patients in whom the investigators consider inappropriate to participate in this study
             (eg, have participated in another drug/instrument study or undergoing another
             drug/instrument study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenyang Liang, MD</last_name>
    <phone>+86-24-28897310</phone>
    <email>doctorliangzi@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyang Liang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Primary percutaneous coronary intervention</keyword>
  <keyword>anticoagulant agents</keyword>
  <keyword>bivalirudin</keyword>
  <keyword>heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

